LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (LEXX) is expected to report earnings on October 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.90 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.2% since its last earnings release on July 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. Lexaria Bioscience Corp. is based in Kelowna, Canada.
Sector
Healthcare
Industry
Biotechnology